MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

181.98 +1.23 (+0.68%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,246,344
Open 181.86
Bid (Size) 176.00 (300)
Ask (Size) 185.00 (100)
Prev. Close 180.75
Today's Range 179.27 - 182.69
52wk Range 110.03 - 185.17
Shares Outstanding 145,800,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Novo Nordisk Shares Plunge as Alzheimer's Drug Trial Fails to Meet Primary Endpoint
Copenhagen, Denmark – November 24, 2025 – Novo Nordisk's (CPH: NOVO B) stock experienced a significant and immediate downturn today, plummeting by over 10% in early trading, following the announcement... 
Via MarketMinute

Performance

YTD
+21.3%
+21.3%
1 Month
+21.9%
+21.9%
3 Month
+30.0%
+30.0%
6 Month
+39.6%
+39.6%
1 Year
+13.1%
+13.1%

More News

Read More
News headline image
Which S&P500 stocks are moving before the opening bell on Monday? ↗
Via Chartmill
News headline image
Earnings Scheduled For October 30, 2025 ↗
Via Benzinga
Biogen Licenses Vanqua Bio’s Immunology Drug In $1.06B Deal ↗
Via Stocktwits
News headline image
Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions
From Biogen Inc.
Via GlobeNewswire
News headline image
AbbVie, Biogen, BioMarin Pharmaceutical, DexCom, and Abbott Laboratories Stocks Trade Up, What You Need To Know
Via StockStory
Topics Economy Government World Trade
News headline image
Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer’s Disease Conference
From Biogen Inc.
Via GlobeNewswire
News headline image
Uncover the latest developments among S&P500 stocks in today's session. ↗
Via Chartmill
News headline image
Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
From Biogen Inc.
Via GlobeNewswire
News headline image
High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen Completes Acquisition of Alcyone Therapeutics
From Biogen Inc.
Via GlobeNewswire
News headline image
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Via Chartmill
News headline image
5 Insightful Analyst Questions From Biogen’s Q3 Earnings Call
Via StockStory
Topics Earnings
News headline image
Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025
From Biogen Inc.
Via GlobeNewswire
News headline image
BIIB Q3 Deep Dive: New Product Launches Offset Guidance Cut, R&D Pipeline Expands
Via StockStory
News headline image
Biogen (NASDAQ:BIIB) Beats Q3 Sales Expectations
Via StockStory
Topics Artificial Intelligence
News headline image
Biogen Sinks Back Into A Buy Zone After Cutting Its Profit Guide ↗
Via Investor's Business Daily
News headline image
Examining the Future: Biogen's Earnings Outlook ↗
Via Benzinga
News headline image
Biogen (BIIB) Reports Earnings Tomorrow: What To Expect
Via StockStory
Topics Artificial Intelligence
News headline image
Biogen's Immunology Pipeline Has Long-Term Potential: Analyst ↗
Via Benzinga
News headline image
Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio
From Biogen Inc.
Via GlobeNewswire
News headline image
3 Profitable Stocks We Steer Clear Of
Via StockStory
News headline image
Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025
From Biogen Inc.
Via GlobeNewswire
News headline image
ARPA-H Taps Former DARPA Innovator to Ignite High-Risk, High-Reward Health Tech Revolution
Via TokenRing AI
Topics Artificial Intelligence Intellectual Property

Frequently Asked Questions

Is Biogen Idec publicly traded?
Yes, Biogen Idec is publicly traded.
What exchange does Biogen Idec trade on?
Biogen Idec trades on the Nasdaq Stock Market
What is the ticker symbol for Biogen Idec?
The ticker symbol for Biogen Idec is BIIB on the Nasdaq Stock Market
What is the current price of Biogen Idec?
The current price of Biogen Idec is 181.98
When was Biogen Idec last traded?
The last trade of Biogen Idec was at 12/04/25 04:00 PM ET
What is the market capitalization of Biogen Idec?
The market capitalization of Biogen Idec is 26.53B
How many shares of Biogen Idec are outstanding?
Biogen Idec has 27B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story